Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Open-label, Two-arm, Phase 4 Study to Evaluate the Effect of Add-on Pioglitazone or Dapagliflozin in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled by Alogliptin and Metformin Therapy

Trial Profile

A Multicenter, Randomized, Open-label, Two-arm, Phase 4 Study to Evaluate the Effect of Add-on Pioglitazone or Dapagliflozin in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled by Alogliptin and Metformin Therapy

Status: Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alogliptin/pioglitazone (Primary) ; Alogliptin; Dapagliflozin; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms EPIDOTE
  • Sponsors Takeda
  • Most Recent Events

    • 02 Dec 2019 Planned number of patients changed from 176 to 232.
    • 02 Dec 2019 Planned End Date changed from 31 Dec 2020 to 5 Jan 2022.
    • 02 Dec 2019 Planned primary completion date changed from 26 Jun 2020 to 22 Dec 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top